Beta cell imaging—from pre-clinical validation to first in man testing
| Autor: | Michael L Schulte, Stéphane Demine, Paul R. Territo, Decio L. Eizirik |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Fluorine Radioisotopes Potassium Channels type 1 diabetes Tetrabenazine Islets of Langerhans Transplantation Informatique appliquée logiciel Review lcsh:Chemistry 5-Hydroxytryptophan Physico-chimie générale 0302 clinical medicine Insulin-Secreting Cells Positron Emission Tomography Computed Tomography Medicine pancreas radiochemistry lcsh:QH301-705.5 Spectroscopy Radiochemistry Technetium Type 2 diabetes General Medicine Magnetic Resonance Imaging Pre-clinical validation 3. Good health Computer Science Applications Type 1 diabetes SPECT type 2 diabetes Beta cell Sodium-Potassium-Exchanging ATPase MRI Beta cell imaging pre-clinical validation 030209 endocrinology & metabolism Nerve Tissue Proteins Computational biology Chimie inorganique Catalysis Inorganic Chemistry 03 medical and health sciences Animals Humans Spectroscopie [état condense] Physical and Theoretical Chemistry Beta (finance) Dipeptidyl-Peptidases and Tripeptidyl-Peptidases Molecular Biology beta cell imaging Pancreas Tomography Emission-Computed Single-Photon business.industry Organic Chemistry Biologie moléculaire Chimie théorique Single-Domain Antibodies Transplantation Chimie organique 030104 developmental biology Diabetes Mellitus Type 1 Spectroscopie [électromagnétisme optique acoustique] PET lcsh:Biology (General) lcsh:QD1-999 Diabetes Mellitus Type 2 Exenatide Radiopharmaceuticals business Catalyses hétérogène et homogène Biomarkers |
| Zdroj: | International journal of molecular sciences, 21 (19 International Journal of Molecular Sciences International Journal of Molecular Sciences, Vol 21, Iss 7274, p 7274 (2020) |
| Popis: | There are presently no reliable ways to quantify human pancreatic beta cell mass (BCM) in vivo, which prevents an accurate understanding of the progressive beta cell loss in diabetes or following islet transplantation. Furthermore, the lack of beta cell imaging hampers the evaluation of the impact of new drugs aiming to prevent beta cell loss or to restore BCM in diabetes. We presently discuss the potential value of BCM determination as a cornerstone for individualized therapies in diabetes, describe the presently available probes for human BCM evaluation, and discuss our approach for the discovery of novel beta cell biomarkers, based on the determination of specific splice variants present in human beta cells. This has already led to the identification of DPP6 and FXYD2γa as two promising targets for human BCM imaging, and is followed by a discussion of potential safety issues, the role for radiochemistry in the improvement of BCM imaging, and concludes with an overview of the different steps from pre-clinical validation to a first-in-man trial for novel tracers. SCOPUS: ar.j info:eu-repo/semantics/published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|